World Lung 2024 – backing for ifinatamab’s pivotal move
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
Why Astra won’t find bladder cancer domination easy
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
A triple-negative breast cancer face-off
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
Tidying up US stomach cancer approvals
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
Opdualag sets its sights on lung
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Merck shuffles the Kelun deck again
Claudin18.2 is out, but the US big pharma opts in to a new project.
CD19 is worth $700m to Merck
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
